Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05456295
Other study ID # 202202450
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 17, 2023
Est. completion date September 2026

Study information

Verified date November 2023
Source University of Iowa
Contact Jason M Wilken, PT, PhD
Phone 3193356857
Email jason-wilken@uiowa.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Carbon fiber custom dynamic orthoses (CDOs) consist of a proximal cuff that wraps around the leg just below the knee, a posterior carbon fiber strut that stores and returns energy during gait, and a carbon fiber foot plate that supports the foot and allows bending of the posterior strut. The proximal cuff is a primary interface between the patient and the CDO and may influence comfort, preference, limb mechanics and loading, and effective stiffness of the CDO. The important role of the proximal cuff has not been examined. The purpose of this study is to determine the effects of CDO proximal cuff design on patient reported outcomes, limb mechanics and loading, and CDO mechanical characteristics.


Description:

Traumatic lower limb injuries often result in poor functional outcomes with long-term negative effects. Carbon fiber custom dynamic orthoses (CDOs) can improve outcomes by reducing pain, supporting the limb, and transferring forces around the limb through the CDO. CDOs consist of a proximal cuff that wraps around the leg just below the knee, a posterior carbon fiber strut that stores and returns energy during gait, and a carbon fiber foot plate that supports the foot and allows bending of the posterior strut. The proximal cuff is a primary interface between the patient and the CDO and may influence comfort, preference, limb mechanics and loading, and effective stiffness of the CDO. Although CDOs are becoming more commonly prescribed following injury the evidence available to guide clinical practice remains limited. The important role of the proximal cuff has not been systematically examined. The purpose of this study is to determine the effects of CDO proximal cuff design on patient reported outcomes, limb mechanics and loading, and CDO mechanical characteristics. Two groups of individuals will participate: individuals with post-traumatic osteoarthritis in the ankle and healthy individuals. Testing will occur without an orthosis and while wearing orthoses with four proximal cuff designs representative of currently available devices: 1) a rigid patellar tendon bearing (PTB) clamshell cuff secured using a mechanical ratcheting system, 2) a PTB shell with a fixed pivot point secured with Velcro, 3) a rigid clamshell cuff secured with Velcro, and 4) a semi-rigid cuff with a flexible outer layer secured with Velcro.


Recruitment information / eligibility

Status Recruiting
Enrollment 34
Est. completion date September 2026
Est. primary completion date September 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility PARTICIPANTS WITH PTOA: Inclusion Criteria: 1. Ages 18-50. 2. Diagnosis of unilateral ankle PTOA. 3. Ability to walk 50 feet at a slow to moderate pace. 4. Ability to walk without a cane or crutch. 5. Ability to read and write in English and provide written informed consent. Exclusion Criteria: 1. Diagnosis with a moderate or severe brain injury. 2. Diagnosis with a physical or psychological condition that would preclude functional testing (e.g. cardiac condition, clotting disorder, pulmonary condition…). 3. Ankle weakness as a result of spinal cord injury or nervous system pathology. 4. Nerve, muscle, bone, or other condition limiting function in the contralateral extremity. 5. Rheumatoid or inflammatory arthritis. 6. Necrosis of any bones in the foot or ankle. 7. Pain of 8/10 or greater during walking. 8. Surgery on study limb anticipated in the next 6 months. 9. Uncorrected visual or hearing impairments. 10. Require use of a stabilizing device (i.e. Ankle Foot Orthosis or Knee Orthosis…) to perform daily activities. 11. Pregnancy 12. Body mass index greater than 40. HEALTHY ABLE-BODIED PARTICIPANTS: Inclusion Criteria: 1. Ages 18-50. 2. Without current complaint of lower extremity pain, spine pain, open wounds or active infection. 3. Ability to hop without pain. 4. Ability to perform a full squat without pain. 5. Ability to read and write in English and provide written informed consent. Exclusion Criteria: 1. Diagnosis with a moderate or severe brain injury. 2. Diagnosis with a physical or psychological condition that would preclude functional testing (e.g. cardiac condition, clotting disorder, pulmonary condition). 3. Medical conditions or injuries that have limited participation in work or exercise in the last 6 months. 4. Medical conditions of injuries limiting function for greater than 6 weeks. 5. Uncorrected visual or hearing impairments. 6. Use of an assistive device. 7. Pregnancy 8. Body mass index greater than 35.

Study Design


Intervention

Device:
Carbon Fiber Custom Dynamic Orthosis (CDO)
The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.

Locations

Country Name City State
United States University of Iowa Iowa City Iowa

Sponsors (2)

Lead Sponsor Collaborator
University of Iowa Bio-Mechanical Composites

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Center of Pressure Velocity Timing Timing of peak center of pressure velocity (percent stance) during gait. Baseline
Other Center of Pressure Velocity Magnitude Magnitude of peak center of pressure velocity (m/s) during gait. Baseline
Other Tibialis Anterior Muscle Activity Electromyography (EMG, % Maximum) of the tibialis anterior during gait. Baseline
Other Peroneus Longus Muscle Activity Electromyography (EMG, % Maximum) of the peroneus longus during gait. Baseline
Other Soleus Muscle Activity Electromyography (EMG, % Maximum) of the soleus during gait. Baseline
Other Medial Gastrocnemius Muscle Activity Electromyography (EMG, % Maximum) of the medial gastrocnemius during gait. Baseline
Other Semi-Structured Interview Semi-structured interviews will also be used to fully capture the patients' perspectives, experience, and opinions associated with the device options they experienced as part of the study. Baseline
Primary Peak Plantar Force (total foot) Force data (N) collected from the total foot (100% of sensor), measured between the foot and orthosis during gait. Baseline
Primary Plantar Force Impulse (total foot) Plantar force impulse (Ns) across the total foot (100% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. Baseline
Primary Peak Plantar Force (forefoot) Force data (N) collected from the total foot (distal 40% of sensor), measured between the foot and orthosis during gait. Baseline
Primary Plantar Force Impulse (forefoot) Plantar force impulse (Ns) across the total foot (distal 40% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. Baseline
Primary Peak Plantar Force (midfoot) Force data (N) collected from the total foot (middle 30% of sensor), measured between the foot and orthosis during gait. Baseline
Primary Plantar Force Impulse (midfoot) Plantar force impulse (Ns) across the total foot (middle 30% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. Baseline
Primary Peak Plantar Force (hindfoot) Force data (N) collected from the total foot (proximal 30% of sensor), measured between the foot and orthosis during gait. Baseline
Primary Plantar Force Impulse (hindfoot) Plantar force impulse (Ns) across the total foot (proximal 30% of sensor) will be calculated using the integral of the force over the stance phase as participants walk in each study condition. Baseline
Primary Numerical Pain Rating Scale Pain will be assessed using a standard 11-point numerical pain rating scale, in which 0 = no pain and 10 = worst pain imaginable. Baseline
Primary PROMIS Patient Reported Outcomes for Physical Function The Patient Reported Outcome Information System (PROMIS) physical function Computer Adaptive Test (CAT) is a computerized assessment measuring physical function. It is scored using a T-score in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. In a given PROMIS domain, a T-score above 50 represents more of the measured variable than the population average. Baseline
Primary PROMIS Patient Reported Outcomes for Pain Interference The Patient Reported Outcome Information System (PROMIS) pain interference Computer Adaptive Test (CAT) is a computerized assessment measuring pain interference. It is scored using a T-score in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. In a given PROMIS domain, a T-score above 50 represents more of the measured variable than the population average. Baseline
Primary Participant Device Preference The participant will rank order their preference for their standard of care device (if applicable), NoCDO, CUFF-A, CUFF-B, CUFF-C, CUFF-D on a questionnaire. Baseline
Secondary Ankle Range of Motion Peak ankle dorsiflexion (degrees) during gait. Baseline
Secondary Peak Ankle Moment Peak ankle moment (Nm/kg) during gait. Baseline
Secondary Peak Ankle Power Peak ankle power (W/kg) during gait. Baseline
Secondary Modified Socket Comfort Score (Comfort) Comfort scores range from 0 = most uncomfortable to 10 = most comfortable. Baseline
Secondary Modified Socket Comfort Score (Smoothness) Comfort scores range from 0 = least smooth to 10 = most smooth. Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1